glp 1 for mash Beyond glucagon-like peptide-1: The promise of polyagonists in metabolic dysfunction–associated steatotic liver disease and metabolic dysfunction–associated steatohepatitis—A systematic review of randomized trials Novo's Wegovy becomes first GLP-1

Signs of low blood sugar include dizziness, shakiness, sweating, confusion, and rapid heartbeat

In both patient populations with pre-existing cardiovascular disease, DPP-4 inhibitors are recommended as one possible third-line therapy besides SGLT-2 inhibitors, thiazolidinediones, or insulin, when therapeutic goals are not met with the previous dual combination

Provides Antioxidant Support : L-Carnosine acts as a cellular protector, supporting the body's natural antioxidant defenses and helping maintain healthy oxidative balance

Merck began trials of the HMG-CoA reductase inhibitor lovastatin in 1980, and won a historic approval in 1987-- showing the medication produced robust reductions in LDL levels